Matches in SemOpenAlex for { <https://semopenalex.org/work/W2562236969> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- W2562236969 abstract "SummaryTheefficacy andsafety ofgemcitabine ata starting doseof800mg m2 administered once a week for3weekswith1 week's restwas investigated inchemonaive patients withadvanced and/or metastatic pancreatic cancer.Of34patients, 32wereevaluable forefficacy, 20patients hadmetastatic stageIVdisease, 25 hada performance statusofI and26(76%)patients hassignificant painon presentation. Allresponses were independently validated byan external oncology review board: two patients achieved a partial response that lasted 5.8and5.2months(6.3%)andsixpatients were stable foratleast 4weeks. Themedianduration of survival forevaluable patients was 6.3months(range 1.6-19.2 months). Thetumourmarkers, CEA,CA 19-9 andCA 195were serially measured in16patients. There was a goodcorrelation withtumourresponsewhen allthree markers were significantly decreased. In4of16patients, tumourmarker levels decreased by> 60%, including thetworesponders, one patient whosurvived for12monthsandone patient whoshowedobjective tumourshrinkage butwas deemedineligible for responseevaluation because thedisease was considered notto bebidimensionally measurable. Symptomatic benefits included improvement inperformance status(17.2%), analgesic requirement (7.4%), painscore (28.6%) andnausea (27.3%). Themean numberofcycles administered was 2.5andthemean dosage received was 890mg m2perinjection. Seventy-four percentofdose administrations were given on schedule. Toxicity, particularly haematological toxicity, reported asthemaximumWHO grade experienced bypatients was mild. Infective episodes were rareandlimited toWHO grade 2 (6.7%). Nauseaandvomitimg was generally modest (WHO grade 3,26.7%). Otherside-effects included mild transient flu-like symptoms(seven patients) andperipheral oedema(three patients), which was notassociated withabnormal cardiac hepatic or renal function. Gemcitabine hasmodestactivity inpancreatic cancer,a limited positive improvement on a rangeofpatient benefit parameters andhasa mildtoxicity profile. For these reasonsandbecause ofitsnovelmodeofaction, gemcitabine warrantsfurther investigation in combination studies inpancreatic cancer." @default.
- W2562236969 created "2017-01-06" @default.
- W2562236969 creator A5054304980 @default.
- W2562236969 creator A5059738597 @default.
- W2562236969 creator A5087972227 @default.
- W2562236969 creator A5091173738 @default.
- W2562236969 date "1996-01-01" @default.
- W2562236969 modified "2023-09-24" @default.
- W2562236969 title "Phase II study ofgemcitabine inpatients withadvanced pancreatic cancer" @default.
- W2562236969 cites W2118512375 @default.
- W2562236969 hasPublicationYear "1996" @default.
- W2562236969 type Work @default.
- W2562236969 sameAs 2562236969 @default.
- W2562236969 citedByCount "0" @default.
- W2562236969 crossrefType "journal-article" @default.
- W2562236969 hasAuthorship W2562236969A5054304980 @default.
- W2562236969 hasAuthorship W2562236969A5059738597 @default.
- W2562236969 hasAuthorship W2562236969A5087972227 @default.
- W2562236969 hasAuthorship W2562236969A5091173738 @default.
- W2562236969 hasConcept C121608353 @default.
- W2562236969 hasConcept C126322002 @default.
- W2562236969 hasConcept C141071460 @default.
- W2562236969 hasConcept C2780210213 @default.
- W2562236969 hasConcept C2780258809 @default.
- W2562236969 hasConcept C29730261 @default.
- W2562236969 hasConcept C71924100 @default.
- W2562236969 hasConcept C90924648 @default.
- W2562236969 hasConceptScore W2562236969C121608353 @default.
- W2562236969 hasConceptScore W2562236969C126322002 @default.
- W2562236969 hasConceptScore W2562236969C141071460 @default.
- W2562236969 hasConceptScore W2562236969C2780210213 @default.
- W2562236969 hasConceptScore W2562236969C2780258809 @default.
- W2562236969 hasConceptScore W2562236969C29730261 @default.
- W2562236969 hasConceptScore W2562236969C71924100 @default.
- W2562236969 hasConceptScore W2562236969C90924648 @default.
- W2562236969 hasLocation W25622369691 @default.
- W2562236969 hasOpenAccess W2562236969 @default.
- W2562236969 hasPrimaryLocation W25622369691 @default.
- W2562236969 hasRelatedWork W126541805 @default.
- W2562236969 hasRelatedWork W1906057952 @default.
- W2562236969 hasRelatedWork W1983876323 @default.
- W2562236969 hasRelatedWork W2052795581 @default.
- W2562236969 hasRelatedWork W2066120777 @default.
- W2562236969 hasRelatedWork W2070583831 @default.
- W2562236969 hasRelatedWork W2187198002 @default.
- W2562236969 hasRelatedWork W2320152548 @default.
- W2562236969 hasRelatedWork W2347614303 @default.
- W2562236969 hasRelatedWork W2355606060 @default.
- W2562236969 hasRelatedWork W2368752931 @default.
- W2562236969 hasRelatedWork W2391039963 @default.
- W2562236969 hasRelatedWork W2412177360 @default.
- W2562236969 hasRelatedWork W2418827130 @default.
- W2562236969 hasRelatedWork W2551399153 @default.
- W2562236969 hasRelatedWork W2556473253 @default.
- W2562236969 hasRelatedWork W3024666654 @default.
- W2562236969 hasRelatedWork W2551171506 @default.
- W2562236969 hasRelatedWork W2778669066 @default.
- W2562236969 hasRelatedWork W3143793396 @default.
- W2562236969 isParatext "false" @default.
- W2562236969 isRetracted "false" @default.
- W2562236969 magId "2562236969" @default.
- W2562236969 workType "article" @default.